Women’s stress levels may be hit harder by economy, report says
WASHINGTON Women may be more prone to stressing out over poor economic conditions, which could have an impact on their health, a report from the Society for Women’s Health Research revealed last week.
Citing a recent survey from the American Psychological Association called “Stress in America,” SWHR noted that women are expressing fear about the current financial situation more than men. Women are also reporting physical and psychological symptoms, including sleep disturbances, headaches, mood swings and changes in appetite, in higher numbers than men.
Three quarters of male respondents to the APA survey expressed fear about the economy, compared to 84 percent of women.
“Women are sometimes more aware of the stress they are feeling,” Stephanie Smith, public education coordinator for the APA and a licensed clinical psychologist in Erie, Colo., said. “They are often more willing to talk about it and admit to the struggles they are having.”
Women also tend to be the primary caretakers for most families, which in times of economic crisis, can add to the burden. “Women have many roles to play in life. They are often the primary caregivers for children and the older generations [aging parents], as well as workers in industry,” Smith said.
In addition, many of the traditional household responsibilities end up falling on the shoulders of women. “As much as things have changed over the years, women still tend to do more of the household work,” Smith said, referring to cooking, cleaning and laundry. “Taken together, these things often lead to more stress in women, because they just have more things to be stressed about.”
Women are more likely to report unhealthy behaviors, including eating poorly and excessive shopping and napping as a response to stress. They are also more likely than men to report physical symptoms of stress, including headaches, exhaustion and depression.
FDA approves Treanda for treatment of Hodgkin’s disease
FRAZER, Pa. The Food and Drug Administration has approved a drug for treating non-Hodgkin’s lymphoma, the drug’s manufacturer announced Monday.
Cephalon announced the agency’s approval of its drug Treanda (bendamustine hydrochloride), an injection for treating indolent B-cell NHL that has progressed up to six months following treatment with Rituxan (rituximab), made by Genentech and Biogen Idec, or a drug regimen that includes Rituxan.
Indolent NHL is a cancer of the lymphatic system that is not curable and often relapses after initial therapy. It affects about 30,000 people in the United States each year, according to the National Cancer Institute.
“Because most patients with indolent non-Hodgkin’s lymphoma eventually become resistant to existing treatments, new treatment options like Treanda are needed to improve patient outcome,” Georgetown University medicine professor and Treanda clinical investigator Bruce Cheson said in a statement.
PharmaSmart to grow its blood pressure management systems in U.S. market
ROCHESTER, N.Y. PharmaSmart International announced last week its intent to penetrate the U.S. market with its blood-pressure management program that has already enjoyed acceptance in the Canadian marketplace, boasting 75 percent penetration.
“Our goal as a company is to change the paradigm in community blood pressure screening,” stated Ashton Maaraba, PharmaSmart’s global vice president of sales and marketing. “We have committed significant resources to ensuring our clients execute at every level, delivering a turnkey program that delivers on the massive blood pressure management opportunity.”
Unlike existing blood pressure programs, which may primarily act as vehicles for third party advertising, PharmaSmart proposes to convert the hypertensive patient into a revenue-generating opportunity, and retain that consumer with an exclusive, pharmacy-branded BP management program, the company stated.
PharmaSmart’s blood pressure management tools and programs allow pharmacies to capitalize on the hypertension opportunity. PharmaSmart’s branded Smart Card offers pharmacists a long-term management tool for their patients that has been found to improve hypertension discovery, consultation, and prescription compliance, all significant challenges in the fight against hypertension, Maaraba noted.
PharmaSmart’s “pharmacy first/patient first” platform seeks to augment the patient-pharmacist relationship through an education program—both point-of-sale training and continuing education—for pharmacists and pharmacy technicians around hypertension. The program includes PharmaSmart’s patented blood-pressure cuff, patient Smart Card management tool, and a patient web portal.
In Canada, PharmaSmart is present in Rexall, Shoppers Drug Mart, Wal-Mart Canada, Loblaws, Le Group Jean Coutu, Safeway Canada and Calgary Coop, among other pharmacies.